Opendata, web and dolomites

ExocyTher SIGNED

Extracellular vesicle production and engineering by turbulence for fistula therapy in thermoreversible hydrogels

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ExocyTher project word cloud

Explore the words cloud of the ExocyTher project. It provides you a very rough idea of what is the project "ExocyTher" about.

trial    fistula    authorized    occlusion    clinical    shelf    companion    scalable    regulatory    off    exocyther    gel    bioreactors    extracellular    device    asc    ev    types    life    temperature    crohn    specially    stress    differentiation    foreseeing    immunomodulatory    20    technological    vehicle    occlusive    scs    translation    shear    efficient    body    evs    surgery    cells    therapeutic    burden    injectable    fill    people    indications    engineering    gains    triggered    secondary    turbulence    priming    sc    fistulas    site    replication    synergic    ascs    disease    release    first    vesicles    standardized    entire    culture    effect    risks    parent    trauma    tract    cancer    uncontrolled    preliminary    capitalizing    yield    regenerative    tackle    induce    label    mitigating    morbidity    considering    recapitulate    gelling    scientific    deg    medicine    millions    storage    rate    health    retain    therapy    vesiculation    basis    mother    adipose    attempt    lt    vascular    inflammatory    medical    stem    building    extended    hampered    administration    cell   

Project "ExocyTher" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 1˙496˙094 €
 EC max contribution 1˙496˙094 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-06-01   to  2025-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 1˙496˙094.00

Map

 Project objective

Extracellular vesicles (EVs) from stem cells (SCs) may recapitulate the therapeutic effect of their mother cells in regenerative medicine while mitigating risks of uncontrolled replication, differentiation and vascular occlusion, offering “off-the-shelf”, storage and shelf-life gains. Yet, the clinical translation of SC EV therapy is hampered by production, engineering and administration challenges. Building on my preliminary results, ExocyTher aims at developing SC EV therapy through: (1) standardized scalable high-yield EV production: I propose the concept of turbulence vesiculation to induce EV release from adipose SCs (ASCs) by a controlled turbulence shear stress integrated to large-scale cell culture in bioreactors; (2) optimised delivery: I propose EV administration in a synergic fistula-occlusive companion gel (injectable at <20°C and gelling at body temperature) in the attempt to fill the entire fistula tract and retain EVs at the site of interest; ExocyTher will tackle the therapy of fistulas, a major health burden related to Crohn's disease or secondary to surgery, cancer therapy or trauma, affecting millions of people in Europe with a high morbidity rate. All-in-one turbulence-triggered vesiculation and priming are expected to provide ASC EVs in high yield and with improved immunomodulatory properties specially for a more efficient therapy of inflammatory Crohn’s disease fistulas. Capitalizing on the use of a gel medical device authorized in Europe as an off-label fistula occlusive EV vehicle and considering key regulatory issues, ExocyTher will set the basis for the first clinical trial on ASC EV fistula therapy. ExocyTher concepts may be extended to other EV parent cell types or therapy indications, foreseeing a high scientific and technological impact.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXOCYTHER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXOCYTHER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More  

MITOvTOXO (2020)

Understanding how mitochondria compete with Toxoplasma for nutrients to defend the host cell

Read More  

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More